BioTuesdays

Tag - CTIC

CTIBiopharmaLogo
Markets

Brookline ups CTI Biopharma PT to $12 from $7.20

Brookline Capital Markets raised its price target for CTI Biopharma (NASDAQ:CTIC) to $12 from $7.20 after the FDA approved Vonjo in myelofibrosis. The stock closed at $3.10, up $1.20, on volume of 108 million shares on...

March 1, 2022
CTIBiopharmaLogo
Markets

BTIG starts CTI Biopharma at buy; PT $7

BTIG initiated coverage of CTI Biopharma (NASDAQ:CTIC) with a “buy” rating and price target of $7. The stock closed at $2.80 on Aug. 6. CTI is a biotechnology company engaged in the development of therapeutics for blood...

August 9, 2021
CTIBiopharmaLogo
Markets

Stifel starts CTI Biopharma at buy; PT $5.50

Stifel initiated coverage of CTI Biopharma (NASDAQ:CTIC) with a “buy” rating and price target of $5.50. The stock closed at $2.34 on May 5. “We think the bull/bear debate on CTI Biopharma centers around the size of the...

May 6, 2021
CTIBiopharmaLogo
Markets

Brookline starts CTI Biopharma at buy; PT $7

Brookline Capital Markets initiated coverage of CTI BioPharma (NASDAQ:CTIC) with a “buy” rating and $7 price target. The stock closed at $3.34 on Oct. 22. CTI is focused on novel targeted therapies for hematologic...

October 23, 2020